✦ LIBER ✦

The role of hydroxyurea in the management of sickle cell disease

✍ Scribed by Sally C Davies; Annette Gilmore

Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 347 KB
Volume: 17
Category: Article
ISSN: 0268-960X
DOI: 10.1016/s0268-960x(02)00074-7

No coin nor oath required. For personal study only.

✦ Synopsis

Sickle cell disease (SCD) is one of the most common genetic diseases with some 250,000 new births each year. Most patients suffer intermittent pain crises and life-threatening events while life expectancy is considerably reduced. Until the last decade management was purely preventative or supportive aimed at symptom control. Apart from stem cell transplant, there is no cure but the oral chemotherapeutic drug hydroxyurea (HU) has now established a role in ameliorating the disease and improving life expectancy for most patients. There are side effects and risks of HU treatment in SCD but for moderate and severely affected patients, the benefits can be significant.

📜 SIMILAR VOLUMES

The role of cytokines in sickle cell dis

The role of cytokines in sickle cell disease

✍ A. C. Makis; E. C. Hatzimichael; K. L. Bourantas 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 121 KB

Recent advances in improving the managem

Recent advances in improving the management of sickle cell disease

✍ Adlette Inati 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Appropriate blood transfusions can both prevent and treat serious complications related to sickle cell disease (SCD), but inevitably lead to iron overload and its complications in terms of morbidity and mortality. Transfusion history and serial serum ferritin level assessments are convenient and cos

Asthma management: Reinventing the wheel

Asthma management: Reinventing the wheel in sickle cell disease

✍ Claudia R. Morris 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 2 views

Role of oxidative stress in the pathogen

Role of oxidative stress in the pathogenesis of sickle cell disease

✍ Erica N. Chirico; Vincent Pialoux 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 368 KB 👁 2 views

## Abstract Sickle cell disease (SCD) is a class of hemoglobinopathy in humans, which causes a disruption of the normal activities in different systems. Although this disease begins with the polymerization of red blood cells during its deoxygenating phase, it can erupt into a cascade of debilitatin

Cost-effectiveness of hydroxyurea in sic

Cost-effectiveness of hydroxyurea in sickle cell anemia

✍ Moore, Richard D.; Charache, Samuel; Terrin, Michael L.; Barton, Franca B.; Ball 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 2 views

The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) demonstrated the efficacy of hydroxyurea in reducing the rate of painful crises compared to placebo. We used resource utilization data collected in the MSH to determine the cost-effectiveness of hydroxyurea. The MSH was a randomized, p

Monitoring toxicity, impact, and adheren

Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease

✍ Amanda M. Brandow; Julie A. Panepinto 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 774 KB

Childhood immune thrombocytopenia (ITP) has a favorable outcome in most cases but severe bleeding may occur, mostly in children with very low platelet counts. Although first-line therapies are well defined, management of refractory ITP is not consensual. Vinblastine (VBL) is one second-line treatmen